Elite Pharmaceuticals, Inc. (ELTP)
0.2888
0.00 (0.00%)
USD |
OTCM |
Aug 28, 16:00
Elite Pharmaceuticals Free Cash Flow : 17.53M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.53M |
| March 31, 2026 | 22.82M |
| December 31, 2025 | 17.24M |
| September 30, 2025 | 21.66M |
| June 30, 2025 | 18.02M |
| March 31, 2025 | 4.930M |
| December 31, 2024 | 3.423M |
| September 30, 2024 | 1.685M |
| June 30, 2024 | 0.0845M |
| March 31, 2024 | -4.091M |
| December 31, 2023 | -3.315M |
| September 30, 2023 | -1.082M |
| June 30, 2023 | -4.456M |
| March 31, 2023 | -2.398M |
| December 31, 2022 | -3.489M |
| September 30, 2022 | 0.031M |
| June 30, 2022 | 3.647M |
| March 31, 2022 | 6.010M |
| December 31, 2021 | 3.734M |
| September 30, 2021 | 1.968M |
| June 30, 2021 | 3.781M |
| March 31, 2021 | 2.864M |
| December 31, 2020 | 2.560M |
| September 30, 2020 | 1.063M |
| June 30, 2020 | -1.221M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.829M |
| December 31, 2019 | -2.727M |
| September 30, 2019 | -3.702M |
| June 30, 2019 | -4.738M |
| March 31, 2019 | -6.812M |
| December 31, 2018 | -5.588M |
| September 30, 2018 | -4.693M |
| June 30, 2018 | -5.545M |
| March 31, 2018 | -5.084M |
| December 31, 2017 | -8.541M |
| September 30, 2017 | -9.167M |
| June 30, 2017 | -9.367M |
| March 31, 2017 | -8.989M |
| December 31, 2016 | -4.584M |
| September 30, 2016 | -5.304M |
| June 30, 2016 | -6.937M |
| March 31, 2016 | -4.714M |
| December 31, 2015 | -9.205M |
| September 30, 2015 | -10.46M |
| June 30, 2015 | -11.03M |
| March 31, 2015 | -17.10M |
| December 31, 2014 | -14.22M |
| September 30, 2014 | -12.95M |
| June 30, 2014 | -9.211M |
| March 31, 2014 | -4.722M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Nektar Therapeutics | -234.03M |
| Daré Bioscience, Inc. | -11.76M |
| Eton Pharmaceuticals, Inc. | -0.268M |
| ANI Pharmaceuticals, Inc. | 167.52M |
| Corcept Therapeutics, Inc. | 106.92M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 10.07M |
| Cash from Investing (Quarterly) | -0.809M |
| Cash from Financing (Quarterly) | -0.1146M |
| Free Cash Flow Per Share (Quarterly) | 0.0082 |
| Free Cash Flow to Equity (Quarterly) | 9.504M |
| Free Cash Flow to Firm (Quarterly) | 9.317M |
| Free Cash Flow Yield | 5.41% |